Опубликована: Янв. 1, 2025
Язык: Английский
Heliyon, Год журнала: 2025, Номер 11(4), С. e42350 - e42350
Опубликована: Янв. 29, 2025
In the present paper, a comprehensive review was conducted to evaluate performance of botulinum toxin type A (BTX-A) in managing various types pain, including myofascial, muscular temporomandibular joint orofacial chronic migraines, and more. Firstly, mechanism action anti-inflammatory effects BTX-A introduced. Following this, recent advancements applications were discussed, with an emphasis on emerging combination therapies, regenerative medicine, personalized treatment strategies. Unlike previous reviews, this study explored broader spectrum pain conditions highlighted BTX-A's versatility potential as long-term, minimally invasive management option. Additionally, importance tailoring emphasized through integration biomarkers, genetic factors, optimized dosing regimens enhance efficacy minimize side effects. Novel combinations such stem cells tissue engineering, identified promising avenues for nerve repair, providing both symptomatic relief regeneration. Furthermore, digital health tools artificial intelligence suggested innovative approaches monitor responses optimize protocols real-time, advancing management. Overall, underscores patient-centered offers recommendations guide future studies optimizing therapy.
Язык: Английский
Процитировано
1
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0